1. Pink Sheet
  3. >>North America

Biosimilar Suffix Naming Idea Trips On Dispensing Problem

 
• By Derrick Gingery

American Pharmacists Association tells FDA during biosimilar guidance hearing that using suffixes to create unique names will be problematic. FDA may be leaning toward the unique names, saying published literature indicates adequate safety tracking is not possible without them.

A pharmacist group identified potential logistical problems that may have poked holes in a brand industry idea to give biosimilars unique non-proprietary names.

FDA remains undecided on the biosimilar naming convention and will review more comments about the issue following a May 11 public hearing on its new biosimilar guidances. The agency still...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America